TRVN
Trevena Inc
Halal Rating :
Last Price
$4.57
Last updated:
Market Cap
-
7D Change
148.37%
1 Year Change
567.15%
Company Overview
Industries
Exchange
Next Earnings Date
Trevena Inc is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders. The company's primary product is OLINVYK® (oliceridine) injection, which is FDA-approved for the management of acute pain in adults severe enough to require an intravenous opioid analgesic.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $325000.0 | $7.35m | - | $521000.0 | 0.00% | 7.09% |
| March 31, 2024 | $20000.0 | $10.41m | - | $513000.0 | 0.00% | 4.93% |
| Dec. 31, 2023 | $-82000.0 | $11.93m | - | $1.87m | 0.00% | 15.64% |
Company Impact
Help us evaluate Trevena Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.